Jefferies Initiates Coverage On Alto Neuroscience with Buy Rating, Announces Price Target of $33
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Andrew Tsai has initiated coverage on Alto Neuroscience (NYSE:ANRO) with a Buy rating and set a price target of $33. This marks a significant moment for ANRO as it gains attention from a major financial institution.
February 27, 2024 | 10:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies has initiated coverage on Alto Neuroscience with a Buy rating and a price target of $33, indicating a positive outlook for the company's stock.
The initiation of coverage by Jefferies, a reputable financial institution, with a Buy rating and a significant price target of $33, suggests a strong vote of confidence in Alto Neuroscience's potential. This is likely to attract investor attention and could lead to a positive short-term impact on ANRO's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100